A Phase 1 interventional study of brentuximab vedotin and cyclophosphamide in Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell and Lymphoma, T-cell, sponsored by Seagen Inc.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-28.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one is the 12th largest by enrollment, is the only one that started in 2011, is one of 6 in phase 1, and was the 7th registered.
397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.
Browse Lymphoma, Large-Cell, Anaplastic studies →1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 1–39
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.
Median enrollment 44 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
15 studies in Lymphoma, Large-Cell, Anaplastic by Pfizer: none open now, 1 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 15 studies in Lymphoma, Large-Cell, Anaplastic by Pfizer, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2011, is one of 8 in phase 1, and was the 10th registered.
Pfizer’s Lymphoma, Large-Cell, Anaplastic studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Lymphoma, Large-Cell, Anaplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety profile of brentuximab vedotin sequentially and in combination with multi-agent chemotherapy in front-line treatment for CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma. It is a phase 1, open-label, dose escalation study in three arms designed to define the MTD, PK, immunogenicity, and anti-tumor activity of brentuximab vedotin in sequence and in combination with multi-agent front-line chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential
Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: prednisone · Drug: doxorubicin · Drug: vincristine
Combination
Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone
Combination
Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone
1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
Also known as: SGN-35
750 mg/m2 IV every 3 weeks (Cycles 3-8)
1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
Also known as: SGN-35
100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
750 mg/m2 IV every 3 weeks (Cycles 1-6)
50 mg/m2 IV every 3 weeks (Cycles 3-8)
50 mg/m2 IV every 3 weeks (Cycles 1-6)
100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
Incidence of adverse events and laboratory abnormalities
Time frame: Through 1 month after last dose
Brentuximab vedotin concentration in blood
Time frame: Through 1 month after last dose
Antitherapeutic antibodies in blood
Time frame: Through 1 month after last dose
Best clinical response
Time frame: Through 1 month after last dose
Progression-free survival
Time frame: Until disease progression or study closure
Overall survival
Time frame: Every 3 months until death or study closure
The record gives a start of Feb 2011, a primary completion of Apr 2013 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large-Cell, Anaplastic →